The purpose of this study is to show that tislelizumab will improve overall survival in participants with Stage IIIB or IV non-small cell lung cancer when compared to docetaxel in second or third-line treatment settings.
This is a randomized, open-label, multicenter Phase 3 study in adult participants with histologically confirmed, locally advanced or metastatic (Stage IIIB or IV), NSCLC (squamous or non-squamous) who have disease progression during or after a platinum-containing regimen.
| Study Arm | Population | Intervention | Comparison | Outcome |
|---|---|---|---|---|
Previously treated (post-platinum) advanced/metastatic NSCLC |
Tislelizumab |
Docetaxel |
Primary Endpoint: OS in ITT and PD-L1 ≥25% populations Key Secondary Endpoints: ORR, DoR, PFS, HRQoL, safety |
